| Literature DB >> 22726358 |
Jon Christensen1, Sara El-Gebali, Manuela Natoli, Thierry Sengstag, Mauro Delorenzi, Susanne Bentz, Hanifa Bouzourene, Martin Rumbo, Armando Felsani, Sanna Siissalo, Jouni Hirvonen, Maya R Vila, Piercarlo Saletti, Michel Aguet, Pascale Anderle.
Abstract
BACKGROUND: The criteria for choosing relevant cell lines among a vast panel of available intestinal-derived lines exhibiting a wide range of functional properties are still ill-defined. The objective of this study was, therefore, to establish objective criteria for choosing relevant cell lines to assess their appropriateness as tumor models as well as for drug absorption studies.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22726358 PMCID: PMC3412164 DOI: 10.1186/1471-2164-13-274
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Most dominant gene expression differences between normal epithelium and all tumor-derived cell lines, and cells with epithelial versus mesenchymal properties. Principal component analysis (PCA) of genomic expression data from human colon carcinoma cell lines (black); laser-dissected tissues (red) of normal human colonocytes (LI), tumor cells (T) and small-intestinal enterocytes (SI); primary cell cultures (green, CAFs); breast cancer cell lines (grey). For each sample 2–3 three replicates were measured.
Rank order of cell lines according to their signature strength
| CAF | 1 | 1 | 8 | 29 | 24 | 23 | 30 | 24 | 6 | 7 |
| MB231 | 2 | 2 | 23 | 30 | 30 | 29 | 27 | 10 | 10 | 21 |
| COLO320 | 3 | 11 | 4 | 17 | 27 | 28 | 10 | 4 | 4 | 29 |
| SW480 | 4 | 4 | 2 | 28 | 25 | 27 | 17 | 17 | 24 | 12 |
| SW620 | 5 | 9 | 1 | 27 | 29 | 22 | 20 | 8 | 7 | 26 |
| Tumor | 6 | 3 | 3 | 20 | 8 | 24 | 26 | 23 | 5 | 20 |
| Normal | 7 | 10 | 26 | 12 | 7 | 14 | 9 | 27 | 2 | 18 |
| Caco,Fl,D | 8 | 15 | 14 | 6 | 6 | 5 | 6 | 21 | 8 | 13 |
| Caco,Fl,U | 9 | 7 | 6 | 5 | 11 | 6 | 2 | 13 | 16 | 1 |
| Caco_CDX2,U | 10 | 6 | 21 | 7 | 13 | 7 | 7 | 18 | 11 | 23 |
| Caco_CDX2,D | 11 | 25 | 25 | 3 | 3 | 3 | 4 | 28 | 29 | 14 |
| JE | 12 | 29 | 30 | 13 | 4 | 12 | 22 | 29 | 3 | 30 |
| KM12 | 13 | 22 | 20 | 10 | 23 | 11 | 21 | 2 | 13 | 5 |
| HCT116 | 14 | 12 | 24 | 21 | 26 | 25 | 18 | 14 | 9 | 24 |
| Caco,Fi,D | 15 | 26 | 27 | 2 | 2 | 2 | 5 | 26 | 17 | 19 |
| T84 | 16 | 17 | 18 | 26 | 9 | 17 | 29 | 22 | 22 | 25 |
| CacoReady | 17 | 19 | 16 | 4 | 5 | 4 | 1 | 20 | 15 | 10 |
| HT29,R | 18 | 16 | 11 | 24 | 16 | 10 | 13 | 5 | 25 | 3 |
| DLD1 | 19 | 13 | 5 | 9 | 18 | 15 | 24 | 3 | 18 | 2 |
| Caco,S | 20 | 27 | 15 | 23 | 22 | 20 | 11 | 9 | 28 | 6 |
| HT29,S | 21 | 18 | 13 | 18 | 15 | 13 | 12 | 1 | 20 | 4 |
| MCF7 | 22 | 24 | 28 | 25 | 28 | 30 | 25 | 15 | 14 | 28 |
| HT29,D | 23 | 28 | 22 | 22 | 10 | 21 | 16 | 25 | 26 | 8 |
| Caco,R | 24 | 14 | 12 | 16 | 19 | 18 | 8 | 7 | 27 | 11 |
| IL | 25 | 30 | 29 | 1 | 1 | 1 | 3 | 30 | 1 | 27 |
| HT29,U | 26 | 23 | 19 | 19 | 14 | 9 | 23 | 16 | 30 | 17 |
| LOVO | 27 | 5 | 7 | 14 | 21 | 16 | 19 | 6 | 12 | 15 |
| LS174T | 28 | 8 | 10 | 15 | 12 | 26 | 28 | 19 | 23 | 16 |
| COLO205 | 29 | 20 | 9 | 11 | 17 | 8 | 15 | 12 | 21 | 22 |
| HCT15 | 30 | 21 | 17 | 8 | 20 | 19 | 14 | 11 | 19 | 9 |
EMT = EMT-related genes, HuISC=“Humanized intestinal stem cell signature”, WNT = direct Wnt targets, Trans_BC = Transporters known to play important role in oral drug absorption, SLC_SI3 = solute carriers expressed at a significantly higher level in small intestinal samples versus colon samples, SLC_PM = solute carriers of the plasma membrane, ABC = ABC transporters, MKI67_CO: Set of genes correlating with MKI67 expression in colon cancer samples, IC50_pos, IC50_neg: Genes with either strong positive or negative correlation between GI50 values of chemotherapeutics and expression across 60 cell line panel (for details of signatures see Additional file 6, methods). Tumor = laser dissected tumor cells, Normal = laser dissected colonocytes, JE, IL = laser dissected enterocytes of the jejunum or ileum, respectively, D = differentiated, U = undifferentiated, Fi = grown on filters, Fl = grown in flasks, R = resistant to methotraxate, S = sensitive to methotrexate.
Figure 2Signatures predictive for survival. Kaplan-Meier representation of overall survival and recurrence-free survival (EMT_RFS) probability over time for patients bearing colon cancers with average high (i.e. relative average expression > 0, green) or low expression (i.e. relative average expression < 0, red) of a selection of gene sets (details see Table 1).
Figure 3Gain of malignant traits and loss of differentiation signature are associated with migratory properties. Migratory properties of intestinal cell lines across membrane in the absence (motility) or presence (chemotaxis) of a FCS gradient (details see “Material and Methods” section). Cell lines are ordered in dependence of rank orders of EMT and SLC_SI3 signatures as shown in Table 1.
Figure 4Caco-2 cells most similar to small intestinal enterocytes with respect to expression of solute carriers. Principal component analysis (PCA) as shown in Figure 1, but carried out on data set filtered using probe sets representing solute carriers.
Figure 5Drug transporter profiles of small intestinal enterocytes most similar to Caco-2 cells. Heatmap of the relative expression levels of transporters known to be relevant for oral drug absorption (Trans_BC). Tumor = laser dissected tumor cells, Normal = laser dissected colonocytes, JE, IL = laser dissected enterocytes of the jejunum or ileum, respectively, D = differentiated, U = undifferentiated, Fi = grown on filters, Fl = grown in flasks. Detailed description of samples in Additional file 5: Table S1.
Figure 6Expression of EMT and HuISC gene sets do not correlate with GI50 values, but with a signature defined by mining NCI databases. Boxplots of the median correlation coefficients between –log (GI50) values and (A) expression of various gene sets in the NCI60 cell line panel or (B) rank orders according to Table 1 of the six intestinal cell lines represented in the NCI60 panel (i.e. SW620, HCT116, HCT15, COLO205, KM12, HT29). Gene sets as described in Table 1.